Literature DB >> 1360916

Racial differences in patients with adenocarcinoma of the endometrium.

H S Cronjé1, S Fourie, M J Doman, J B Helms, J T Nel, L Goedhals.   

Abstract

OBJECTIVE: To determine the differences between white and black women with regard to the presentation and behavior of adenocarcinoma of the endometrium.
METHOD: Records of 273 (68%) white patients and 117 (32%) black patients with endometrial adenocarcinoma were reviewed in Bloemfontein, South Africa. Survival data was calculated according to the direct method where losses in follow-up were regarded as tumor deaths.
RESULTS: Most patients (82%) were treated by pre-operative radium followed by total abdominal hysterectomy and bilateral salpingo-oophorectomy, with post-operative external irradiation where indicated. Pre-operatively, fewer black women had reached FIGO stage I, while a larger number had advanced to stages II-IV (P = 0.0024). In addition, the tumor differentiation was more often poor in the black group (P < 0.0001). Ten-year follow-up was achieved in 84% of the white patients and 51% of the black patients and the 10-year survival figures were 67% for white patients and 28% for blacks (P < 0.0001).
CONCLUSION: Endometrial adenocarcinoma is a more aggressive disease in black women than it is in whites.

Entities:  

Mesh:

Year:  1992        PMID: 1360916     DOI: 10.1016/0020-7292(92)90659-7

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  2 in total

1.  Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival.

Authors:  Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber
Journal:  Am J Public Health       Date:  2004-12       Impact factor: 9.308

2.  The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Rodney P Rocconi; Heather A Lankes; William E Brady; Paul J Goodfellow; Nilsa C Ramirez; Ronald D Alvarez; William Creasman; José R Fernández
Journal:  Gynecol Oncol       Date:  2015-11-18       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.